

CLINICAL TRIAL | A Randomized Double-Blind Controlled Trial of Everolimus in Children and Adolescents with *PTEN* Mutations (IRB 17-511)

Individuals with *PTEN* mutations have an increased risk of developing cognitive and behavioral deficits; however, there are no agents currently approved to treat these problems. The purpose of this study is to establish if the approved cancer and anti-transplant rejection drug everolimus is safe for individuals with *PTEN* mutations and to determine if the drug has any effect on their cognitive and behavioral problems.

Study sites include the Cleveland Clinic, Boston Children's Hospital, and Stanford University. A total of 46 patients were enrolled. Rabi Hanna, MD, is the principal investigator of the Cleveland site.

This study is closed to enrollment, meaning that patient visits are completed. The study is currently in the data analysis phase. Please stay tuned for study results and the next phases of the clinical trial.